Altos Labs

/
Executive Leadership

Hal Barron, MD

CEO, Founder and Board Co-Chair

CEO, Founder and Board Co-Chair

Hal Barron, MD

"It’s clear from work by Shinya Yamanaka, and many others since his initial discoveries that cells have the ability to rejuvenate, resetting their epigenetic clocks and erasing damage from a myriad of stressors. These insights, combined with major advances in a number of transformative technologies, inspired us to establish Altos with a transformative mission, to reverse disease for patients. I care deeply about making a difference for patients and find the idea of disease reversal to be an incredibly inspiring possibility."

Dr. Hal Barron is the CEO, Founder and Board Co-Chair of Altos Labs.

Prior to joining Altos, Hal was Chief Scientific Officer and President, R&D at GSK, where he was responsible for all research and development activities globally across pharmaceutical molecules and vaccine candidates including life-cycle management for all approved products. He remains a non-executive director on GSK’s Board of Directors.

Prior to joining Altos, Hal was Chief Scientific Officer and President, R&D at GSK, where he was responsible for all research and development activities globally across pharmaceutical molecules and vaccine candidates including life-cycle management for all approved products. He remains a non-executive director on GSK’s Board of Directors.

Prior to joining GSK, Hal was President, R&D at Calico Labs, an Alphabet-funded company. Prior to this role, he was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, Hal was Senior Vice President of Development and Chief Medical Officer. He was a non-executive director and chair of the Science & Technology Committee at Juno Therapeutics until March 2018, when it was acquired by Celgene Corporation. He also previously served as a non-executive Board director of Grail until it was acquired by Illumina in 2021. He was also an Advisory Board Member of Verily Life Sciences until 2021.

Prior to joining GSK, Hal was President, R&D at Calico Labs, an Alphabet-funded company. Prior to this role, he was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, Hal was Senior Vice President of Development and Chief Medical Officer. He was a non-executive director and chair of the Science & Technology Committee at Juno Therapeutics until March 2018, when it was acquired by Celgene Corporation. He also previously served as a non-executive Board director of Grail until it was acquired by Illumina in 2021. He was also an Advisory Board Member of Verily Life Sciences until 2021.

Hal holds a BS in Physics from Washington University in St. Louis and a MD from Yale University. He completed his training in Internal Medicine and Cardiology at the University of California, San Francisco. Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals. He also continues to teach as an Adjunct Professor of Epidemiology and Biostatistics at the University of California, San Francisco.

Hal holds a BS in Physics from Washington University in St. Louis and a MD from Yale University. He completed his training in Internal Medicine and Cardiology at the University of California, San Francisco. Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals. He also continues to teach as an Adjunct Professor of Epidemiology and Biostatistics at the University of California, San Francisco.

Hal Barron, MD

"It’s clear from work by Shinya Yamanaka, and many others since his initial discoveries that cells have the ability to rejuvenate, resetting their epigenetic clocks and erasing damage from a myriad of stressors. These insights, combined with major advances in a number of transformative technologies, inspired us to establish Altos with a transformative mission, to reverse disease for patients. I care deeply about making a difference for patients and find the idea of disease reversal to be an incredibly inspiring possibility."